Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Journal of the American Academy of Dermatology|November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.Dermatology and Therapy|June 21, 2024
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with BaricitinibBrittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, et al.Journal of the American Academy of Dermatology|February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.JAMA Dermatology|August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical TrialBrett King, Justin Ko, Ohsang Kwon, et al.Journal of the American Academy of Dermatology|October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2Brett King, Manabu Ohyama, Maryanne Senna, et al.American Journal of Clinical Dermatology|March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.Journal of Crohn'S & Colitis|June 10, 2025
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 studyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.Journal of Crohn'S & Colitis|June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial resultsVipul Jairath, Fernando Magro, Marijana Protic, et al.Pageof 9